Effect of in vivo administration of Tetrahymena pyriformis on the in vitro toxoplasmacidal activity of mouse peritoneal macrophages

, Kim, C T; , Chung, P R; , Im, K I

doi:1991.29.2.129

Korean J Parasito > Volume 29(2):1991 > Article

Original Article


Korean J Parasitol. 1991 Jun;29(2):129-137. English. Published online Mar 20, 1994. http://dx.doi.org/10.3347/kjp.1991.29.2.129
Copyright © 1991 by The Korean Society for Parasitology


Effect of in vivo administration of Tetrahymena pyriformis on the in vitro toxoplasmacidal activity of mouse peritoneal macrophages
C T Kim,P R Chung and K I Im
Department of Parasitology, College of Medicine, and Institute of Tropical Medicine, Yonsei University, Seoul 120-752, Korea.


Abstract
Tetrahymena pyriformis is a free-living ciliate protozoan in the freshwater system. Experiments were carried out to determine whether intraperitoneal administration of T. pyriformis (GL strain) to mice activates macrophages to be able to kill Toxoplasma gondii tachyzoites in vitro. Mice were also injected intraperitoneally with several synthetic activators; dimethyldioctadecylammonium bromide (DDA), dextran sulfate, complete Freund's adjuvant (CFA) as well as Toxoplasma and Tetrahymena lysates in order to activate mouse peritoneal macrophages. One week after the administration of activators, peritoneal cells were harvested and the adherent macrophages were challenged with Toxoplasma tachyzoites. Macrophage monolayers were then fixed with absolute methanol after washing, and stained with Giemsa solution. The percentage of the adherent cells infected and total number of organisms per 100 macrophages were calculated to make toxoplasmacidal activity of macrophages according to the cultivation time. Peritoneal macrophages from mice administered with Tetrahymena exhibited significant protection against target parasites as compared with those treated with synthetic activators. Among non-biological synthetic activators, DDA was evaluated as an excellent activator.

Figures


	Fig. 1 T. pyriformis trophozoites.


	Fig. 2 Mouse peritoneal macrophage activated with T. pyriformis and infected with T. gonidii tachyzoites, 20 hrs after incubation.


	Fig. 3 Perentages of mouse peritoneal macrophages treated with various activators and infected with live T. gonidii


	Fig. 4 Total numbers of live T. gonidii per 100 mouse peritoneal macrophages treated with various activators.


	Fig. 5 Perentages of mouse peritoneal macrophages treated with various activators and infected with heat-killed T. gonidii


	Fig. 6 Total numbers of heat-killed T. gonidii per 100 mouse peritoneal macrophages treated with various activators.

Tables


	Table 1 Anti-Toxoplasma activities of peritoneal macrophages from mice inoculated with various activators^*


	Table 2 Anti-Toxoplasma activities of peritoneal macrophages from mice inoculated with various non-specific activators^*

References


1.	Adlam C, et al. Nature 1972;235:219–220.

2.	Bomford R, Christie GH. Mechanisms of macrophage activation by corynebacterium parvum. II. In vivo experiments. Cell Immunol 1975;17(1):150–155.

3.	Christie GH, Bomford R. Mechanisms of macrophage activation by Corynebacterium parvum. I. In vitro experiments. Cell Immunol 1975;17(1):141–149.

4.	Ghaffar A, Cullen RT, Woodruff MA. Further analysis of the anti-tumour effect in vitro of peritoneal exudate cells from mice treated with Corynebacterium parvum. Br J Cancer 1975;31(1):15–24.

5.	Hilgers LA, Snippe H, Jansze M, Willers JM. Effect of in vivo administration of different adjuvants on the in vitro candidacidal activity of mouse peritoneal cells. Cell Immunol 1985;90(1):14–23.

6.	Hoffman GL, Landolt M, Camper JE, Coats DW, Stookey JL, Burek JD. A disease of freshwater fishes caused by Tetrahymena corlissi Thompson, 1955, and a key for identification of holotrich ciliates of freshwater fishes. J Parasitol 1975;61(2):217–223.

7.	Kaplan AM, Morahan PS, Regelson W. Induction of macrophage-mediated tumor-cell cytotoxicity by pyran copolymer. J Natl Cancer Inst 1974;52(6):1919–1923.

8.	Krahenbuhl JL, Ruskin J, Remington JS. The use of killed vaccines in immunization against an intracellular parasite: Toxoplasma gondii. J Immunol 1972;108(2):425–431.

9.	Larson CL, et al. Nature 1971;229:243–244.

*10.*	Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193(1):265–275.

*11.*	Mackaness GB. The influence of immunologically committed lymphoid cells on macrophage activity in vivo. J Exp Med 1969;129(5):973–992.

*12.*	Madraso ED, Cheers C. Polyadenylic acid-polyuridylic acid (poly A : U) and experimental murine brucellosis. II. Macrophages as target cells of poly A : U in experimental brucellosis. Immunology 1978;35(1):77–84.

*13.*	Makioka A, et al. Jap J Parasitol 1982;31(6):561–568.

*14.*	Makioka A, et al. Jap J Parasitol 1983;22(3):203–210.

*15.*	McLeod R, Estes RG, Mack DG. Effects of adjuvants and Toxoplasma gondii antigens on immune response and outcome of peroral T. gondii challenge. Trans R Soc Trop Med Hyg 1985;79(6):800–804.

*16.*	Schultz RM, Papamatheakis JD, Chirigos MA. Interferon: an inducer of macrophage activation by polyanions. Science 1977;197(4304):674–676.

*17.*	Smrkovski LL, Strickland GT. Rodent malaria: BCG-induced protection and immunosuppression. J Immunol 1978;121(4):1257–1261.

*18.*	Suzuki Y, Orellana MA, Schreiber RD, Remington JS. Interferon-gamma: the major mediator of resistance against Toxoplasma gondii. Science 1988;240(4851):516–518.

*19.*	Watanabe Y, Ikeda M. Isolation and characterization of the division protein in Tetrahymena pyriformis. Exp Cell Res 1965;39(2):443–452.

*20.*	Woodruff MF, Warner NL. Effect of Corynebacterium parvum on tumor growth in normal and athymic (nude) mice. J Natl Cancer Inst 1977;58(1):111–116.